NEA Management Company’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
Sell
-6,138,797
Closed -$295M 50
2020
Q1
$295M Hold
6,138,797
15.4% 1
2019
Q4
$288M Hold
6,138,797
13.62% 1
2019
Q3
$145M Hold
6,138,797
12.02% 2
2019
Q2
$185M Hold
6,138,797
12.93% 1
2019
Q1
$138M Hold
6,138,797
7.14% 2
2018
Q4
$112M Buy
6,138,797
+645,161
+12% +$10.1M 4.43% 5
2018
Q3
$99.4M Hold
5,493,636
4.29% 7
2018
Q2
$54.7M Hold
5,493,636
2.56% 11
2018
Q1
$29.2M Buy
5,493,636
+2,000,000
+57% +$14.3M 1.3% 18
2017
Q4
$29.7M Hold
3,493,636
1.23% 20
2017
Q3
$51M Hold
3,493,636
1.79% 14
2017
Q2
$65.5M Hold
3,493,636
2.38% 8
2017
Q1
$74.4M Hold
3,493,636
2.59% 6
2016
Q4
$53.1M Buy
+3,493,636
New +$47.5M 2.11% 9

Other funds holding RARX

NEA Management Company's RARX Position: Q2 2020 in Review

NEA Management Company sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 6,138,797 shares — an estimated $295M sold.

NEA Management Company first reported a position in RARX in Q4 2016 and held it in 14 quarters. The position peaked at $295M in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

  • NEA Management Company reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • NEA Management Company sold 6,138,797 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $295M.
  • NEA Management Company first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 14 quarters.
  • NEA Management Company's Ra Pharmaceuticals, Inc. Common Stock position peaked at $295M in Q1 2020.
  • 1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on NEA Management Company's 13F filing for Q2 2020, filed 5 Aug 2020.